Menu
Search
|

Menu

Close
X

Catalyst Biosciences Inc CBIO.OQ (NASDAQ Stock Exchange Capital Market)

10.65 USD
-0.31 (-2.83%)
As of 9:19 PM IST
chart
Previous Close 10.96
Open 10.88
Volume 5,923
3m Avg Volume 77,218
Today’s High 11.04
Today’s Low 10.57
52 Week High 37.00
52 Week Low 5.47
Shares Outstanding (mil) 4.31
Market Capitalization (mil) 24.57
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
1
FY16
0
FY15
2
EPS (USD)
FY18
-1.748
FY17
-9.706
FY16
-21.765
FY15
-204.776
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
43.72
5.69
Price to Book (MRQ)
vs sector
0.81
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
19.01
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-68.74
15.05
Return on Equity (TTM)
vs sector
-83.55
16.62

EXECUTIVE LEADERSHIP

Augustine Lawlor
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Nassim Usman
President, Chief Executive Officer, Director, Since 2015
Salary: --
Bonus: --
Fletcher Payne
Chief Financial Officer, Since 2015
Salary: --
Bonus: --
Grant Blouse
Vice President - Translational Research, Since 2018
Salary: --
Bonus: --
Andrew Hetherington
Vice President - Manufacturing Operations, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

260 Littlefield Ave
SOUTH SAN FRANCISCO   CA   94080-6902

Phone: +1650.7450655

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

SPONSORED STORIES